name

Vivek Garipalli

HQ Location: USA

RANK #141

Vivek Garipalli is co-founder, board member and CEO of Clover Health. He is a member of the board of directors of Character Biosciences. He is a member of the board of directors of Thyme Care. He is also an executive director at Wormhole Capital. He has also served on the board of directors of Medically Home. He was a member of the board of directors at Driver & SALIDO. He is also a co-founder of CarePoint Health. He is a serial health care entrepreneur and reorganization expert specializing in innovations designed to expand access to quality health care and improve patient outcomes. In 2008, he founded CarePoint Health, a fully integrated health system in New Jersey. Through his role at CarePoint, whose mission is to serve uninsured and underinsured patients, he has seen firsthand the inconsistencies between providers and insurance companies. Prior to CarePoint, he owned and operated various outpatient facilities. He began his career in finance, holding positions at Credit Suisse First Boston, J.P. Morgan Partners and Blackstone Group. He has been active in the medical technology industry, serving on the boards of Flatiron Health and Doctor Evidence. He holds a bachelor's degree in Business Administration from Emory University, specializing in entrepreneurship. He is a board observer at Cityblock Health. Served on the board of directors of Flatiron.

Numbers of Unicorns

3

1941

Rank (Xs)

#141

Investments

24

Exits

6

Numbers of Unicorns

3

1941

Rank (Xs)

#141

Investments

24

Exits

6

All Unicorns

Logo

Company name

ENTRY ROUND

VALUATION at entry ($M)

VALUATION 

Carta

Carta

Series C

$5M

1480

$7400M

Cityblock Health

Cityblock Health

Series A

$20M

285

$5700M

Swiftly

Swiftly

$40.2M

25

$1000M

All $100M+

Company name

ENTRY ROUND

VALUATION at entry ($M)

VALUATION 

275

Arrive Health

$5.5M

22

$123M

4130

Petal

$7.1M

113

$800M

4759

S Quotient Analyzers Pvt. Ltd.

$30M

9

$284M

4660

Ribbon (Enterprise Systems)

Series A

$45M

6

$283.5M

The information is provided for informational purposes.  The company does not bear any responsibility for the published data.